How could the potential FDA approval of VDPHL01 affect Eli Lilly and Company?
New hair loss treatment could increase competition for major pharma players If the Food and Drug Administration approves VDPHL01, it would introduce a new, non-hormonal oral therapeutic for pattern hair loss. This drug, an extended-release minoxidil formulation, could serve as an alternative to finasteride, the only currently approved oral prescription. This development increases competition in a market valued at over $30 billion by 2028, potentially impacting the market share and revenue streams of established pharmaceutical companies like Eli Lilly and Company.
- Effect
- Mild negative
- How direct
- Brind's reasoning
- When
- Within months
- The story
- Gone quiet
How it reaches Eli Lilly and Company
-
Veradermics, Incorporated is seeking approval from the FDA for its lead therapy, VDPHL01, which targets hair loss. The company recently released positive Phase 3 trial results for VDPHL01, an extended-release minoxidil formulation. In the study, 78.8% of patients on the daily dose and 85% on the twice-daily dose reported improvements in hair coverage compared to 35.3% in the placebo group.
The full event1independent outlet -
If approved, VDPHL01 would be the first oral minoxidil approved, filling a gap since the last FDA-approved hair restoration drug almost three decades ago. This introduction of a new, potentially superior, non-hormonal option increases competitive pressure on existing treatments in the $30 billion market, which affects major pharmaceutical companies like Eli Lilly and Company.
No report states this step directly. Brind drew it from the reporting on each side of it, so treat it as an informed guess.
-
American pharmaceutical company
Everything about Eli Lilly and Company
Tap any step to see the evidence behind it.
The facts so far
As reported. Each one links to where it comes from.
- VDPHL01 is an extended-release minoxidil formulation.fool.com
- It could be the first non-hormonal oral therapeutic for pattern hair loss.fool.com
- The market for pattern hair loss is worth more than $30 billion by 2028.fool.com
- VDPHL01 could garner a 48% market share among current hair restoration therapies.fool.com
Why it matters
The hair loss market is vast and growing, affecting an estimated 50 million men and 30 million women in the U.S. The introduction of a new, effective, and non-hormonal treatment could significantly shift the competitive landscape. For major pharmaceutical companies, this means facing a new, potentially dominant competitor that offers a superior safety profile compared to existing hormonal options.
This situation is critical because the market currently relies heavily on finasteride, which is hormonal and carries unwanted side effects. VDPHL01's potential approval addresses this gap, positioning it as a major disruptive force. Other pharmaceutical companies are constantly seeking to innovate in this space, and the success of VDPHL01 could set a new standard for efficacy and safety in hair restoration therapies.
What we don't know yet
- What is the timeline for the New Drug Application submission?
- How quickly will healthcare professionals adopt VDPHL01 compared to existing treatments?
What would change this answer
Who else could feel it
Other possible ripples from the same event.
Reporting
- fool.comOct 25
Keep going
Brind's analysis is written by AI from the reporting linked above and can be wrong. This explainer is a possibility worth considering, not a forecast: steps marked as Brind's reasoning are not stated in the reporting. It is not investment advice; do your own research.